| [3] |
Urbaniak A，Jablonska K，Podhorska-Okolow M，et al.Prolactin-induced protein （PIP）-characterization and role in breast cancer progression[J].Am J Cancer Res，2018，8（11）：2150-2164.
|
| [4] |
Jablonska K，Grzegrzolka J，Podhorska-Okolow M，et al.Prolactin-induced protein as a potential therapy response marker of adjuvant chemotherapy in breast cancer patients[J].Am J Cancer Res，2016，6（5）：878-893.
|
| [5] |
Hassan MI，Waheed A，Yadav S，et al.Prolactin inducible protein in cancer，fertility and immunoregulation：structure，function and its clinical implications[J].Cell Mol Life Sci，2009，66（3）：447-459.
|
| [6] |
Ihedioha O，Blanchard AA，Balhara J，et al.The human breast cancer-associated protein，the prolactin-inducible protein（PIP），regulates intracellular signaling events and cytokine production by macrophages[J].Immunol Res，2018，66（2）：245-254.
|
| [7] |
Edechi CA，Nasr MR，Karim A，et al.The prolactin inducible protein/gross cystic disease fluid protein-15 deficient mice develop anomalies in lymphoid organs[J].Immunobiology，2019，224（6）：811-816.
|
| [8] |
López-Otín C，Diamandis EP.Breast and prostate cancer：an analysis of common epidemiological，genetic，and biochemical features[J].Endocr Rev，1998，19（4）：365-396.
|
| [9] |
Takeda Y，Tsuta K，Shibuki Y，et al.Analysis of expression patterns of breast cancer-specific markers （mammaglobin and gross cystic disease fluid protein 15） in lung and pleural tumors[J].Arch Pathol Lab Med，2008，132（2）：239-243.
|
| [10] |
Ni YB，Tsang JYS，Shao MM，et al.GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer[J].Breast Cancer Res Treat，2018，169（1）：25-32.
|
| [11] |
Borhan WM，Cimino-Mathews AM，Montgomery EA，et al.Immunohistochemical Differentiation of Plasmacytoid Urothelial Carcinoma From Secondary Carcinoma Involvement of the Bladder[J].Am J Surg Pathol，2017，41（11）：1570-1575.
|
| [12] |
Edechi CA，Ikeogu N，Uzonna JE，et al.Regulation of Immunity in Breast Cancer[J].Cancers （Basel），2019，11（8）：1080.
|
| [13] |
Park JH，Kim JH.Pathologic differential diagnosis of metastatic carcinoma in the liver[J].Clin Mol Hepatol，2019，25（1）：12-20.
|
| [16] |
刘君.重症肺炎患者血泌乳素水平变化及其临床意义[D].石家庄：河北医科大学，2016.
|
| [19] |
Osawa M，Horiuchi H，Tian W，et al.Divergent evolution of the prolactin-inducible protein gene and related genes in the mouse genome[J].Gene，2004，325：179-186.
|
| [14] |
Lagendijk JH，Mullink H，van Diest PJ，et al.Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colonic and breast origin.Comparison between a statistical and an intuitive approach[J].J Clin Pathol，1999，52（4）：283-290.
|
| [15] |
Sriram R，Lo V，Pryce B，et al.Loss of periostin/OSF-2 in ErbB2/Neu-driven tumors results in androgen receptorpositive molecular apocrine-like tumors with reduced Notch1 activity[J].Breast Cancer Res，2015，17（1）：7.
|
| [17] |
Sharif R，Bak-Nielsen S，Hjortdal J，et al.Pathogenesis of Keratoconus：The intriguing therapeutic potential of Prolactin-inducible protein[J].Prog Retin Eye Res，2018，67：150-167.
|
| [18] |
Priyadarsini S，Hjortdal J，Sarker-Nag A，et al.Gross cystic disease fluid protein-15/prolactin-inducible protein as a biomarker for keratoconus disease[J].PLoS One，2014，9（11）：e113310.
|
| [20] |
Hassan MI，Waheed A，Yadav S，et al.Prolactin inducible protein in cancer，fertility and immunoregulation：structure，function and its clinical implications[J].Cell Mol Life Sci，2009，66（3）：447-459.
|
| [21] |
Striebel JM，Dacic S，Yousem SA.Gross cystic disease fluid protein-（GCDFP-15）：expression in primary lung adenocarcinoma[J].Am J Surg Pathol，2008，32（3）：426-432.
|
| [1] |
Herbst RS，Morgensztern D，Boshoff C.The biology and management of non-small cell lung cancer[J].Nature，2018，553（7689）：446-454.
|
| [2] |
Ihedioha OC，Shiu RP，Uzonna JE，et al.Prolactin-Inducible Protein：From Breast Cancer Biomarker to Immune Modulator-Novel Insights from Knockout Mice[J].DNA Cell Biol，2016，35（10）：537-541.
|
